Cargando…
Locoregional progression-free survival of bone metastases from differentiated thyroid cancer
To evaluate the locoregional progression-free survival (LPFS) of bone metastatic lesions from differentiated thyroid cancer (DTC) after radioiodine therapy (RAIT) and to define its influencing factors, we performed a retrospective cohort analysis of 89 patients with bone metastases from DTC who rece...
Autores principales: | Luo, Jiaxin, Yin, Weili, Lin, Qiuxia, Wu, Juqing, Chen, Pan, Ling, Yuanna, Wang, Jing, Li, Zhen, Pan, Liqin, Chen, Yanying, Ouyang, Wei, Feng, Huijuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bioscientifica Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010805/ https://www.ncbi.nlm.nih.gov/pubmed/35175222 http://dx.doi.org/10.1530/EC-22-0042 |
Ejemplares similares
-
BRAF V600E and lymph node metastases in papillary thyroid cancer
por: Chen, Pan, et al.
Publicado: (2020) -
The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib
por: Ling, Yuanna, et al.
Publicado: (2023) -
Incorporation size of lymph node metastasis focus and pre-ablation stimulated Tg could more effectively predict clinical outcomes in differentiated thyroid cancer patients without distant metastases
por: Xie, Jiahao, et al.
Publicado: (2023) -
Corrigendum: Incorporation size of lymph node metastasis focus and pre-ablation stimulated Tg could more effectively predict clinical outcomes in differentiated thyroid cancer patients without distant metastases
por: Xie, Jiahao, et al.
Publicado: (2023) -
Clinical significance of the BRAF(V600E) mutation in PTC and its effect on radioiodine therapy
por: Zhu, Guoquan, et al.
Publicado: (2019)